We have several drug discovery programs (see Drug Pipeline) aimed at restoring the vigor and functionality of tumor-infiltrating T and NK cells
While other projects aim to find tumor-selective ways to stimulate such cell populations. We have also initiated drug discovery efforts with the objective of stimulating the maturation and activation of tumor antigen-presenting dendritic cells (DC). We are conducting this work in a modality independent manner. Each of these drug discovery programs addresses one or more therapeutic nodes and will gradually increase the breadth and depth of our growing therapeutic portfolio. Our two most advanced programs are AB928 (dual A2aR/A2bR antagonist) and AB154 (anti-TIGIT antibody).